CRSP
CRISPR Therapeutics AG
Is CRSP Halal?
Gene editing for therapy — scholarly consultation recommended.
What You Should Know
FDA-approved CRISPR therapy for sickle cell. Therapeutic gene editing generally permitted by scholars but not unanimous. Its March 31, 2026 Form 10-Q reports $2,725.820 million of assets, $787.638 million of conservative debt and leases, $423.308 million of cash, $2,018.477 million of marketable securities and $1.458 million of quarterly revenue. Debt/assets is 28.89%, but liquidity/assets is 89.58% and fails the examined 33.33% limits; the activity and income numerators remain incomplete.
⚠️ Concerns
- •Ethical debate
- •Scholar consultation needed
- •Liquidity/assets exceeds examined limits
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
787.638 / 2,725.82
2,441.785 / 2,725.82
423.308 / 2,725.82
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 89.58%, above the examined 33.333% limit; debt/assets is 28.89% and receivables-plus-cash/assets is 15.53%.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 89.58%, above the examined 33.33% limit; debt/assets is 28.89% and receivables-plus-cash/assets is 15.53%.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 89.58%, above the examined Malaysia 33% limit; debt/assets is 28.89%. This calculation is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed and reproducible historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
CRISPR Therapeutics develops gene-editing therapies. Therapeutic healthcare is generally permissible, while human-germline boundaries, licensing and product allocation require qualified scholarly review.
Limitation: The filing does not provide a universal prohibited-activity or income numerator across collaborations and therapeutic programs.
Purification
CRISPR Therapeutics does not separately disclose a scholar-approved non-compliant income numerator or purification percentage.
Inputs, assumptions and primary sources
- Amounts are USD millions from CRISPR Therapeutics' March 31, 2026 Form 10-Q.
- Conservative debt includes $585.470 million long-term debt and $202.168 million of current and noncurrent operating-lease liabilities.
- Cash and cash equivalents are $423.308 million and current available-for-sale debt securities are $2,018.477 million; no separate accounts-receivable balance is tagged in the filing facts.
- Quarterly collaboration and grant revenue is $1.458 million. The filing does not separately disclose a scholar-universal non-compliant income numerator.
- Therapeutic gene editing is generally permissible in the retained qualitative analysis, but bioethics, licensing and end-use questions remain school- and case-dependent.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →